Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases
Adding pemetrexed-platinum chemotherapy to first-line gefitinib for EGFR-mutant NSCLC patients with BrMs in China represented a cost-effective treatment strategy from the perspective of the Chinese healthcare system.
Authors
- Maolin Chen (ORCID: https://orcid.org/0000-0002-0806-4223)
- Ziying Zhao
- Jiang Du (ORCID: https://orcid.org/0000-0002-9203-2450)
- Yanan Zhao (ORCID: https://orcid.org/0000-0002-6634-2949)
- Qiao Liu (ORCID: https://orcid.org/0000-0002-6620-1994)
- Li Fang (ORCID: https://orcid.org/0000-0002-1076-7729)
- Liling Zhao (ORCID: https://orcid.org/0009-0008-4710-1825)
Institutions
- Central South University (CN)
- Zhengzhou University (CN)
- Henan Provincial Chest Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1186/s12913-025-13322-3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00